Nov 10 (Reuters) - Becton Dickinson and Co (BDX.N) on Thursday forecast a sharp decline in COVID-19 test sales for fiscal year 2023 as it expects the testing market to shrink next year with infections dropping.
A Rhode Island jury concluded Becton Dickinson & Co. must pay $4.8 million in damages to a man who blamed a hernia mesh sold by one of the company’s units for damaging his bowels and leaving him unable to work, according to his attorney.
Becton Dickinson’s recall of devices used to access blood vessels through a patient’s bone has been labeled a Class I event by the Food and Drug Administration.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired MedKeeper, a provider of ...
BD (Becton, Dickinson and Company) (NYSE: BDX) today announced it has completed the acquisition of Parata Systems. Parata advances BD's...
BD has begun a voluntary recall of many of its intraosseous needle kits and delivery systems, citing a handful of potential safety issues with the devices.
BD teamed up with the Mayo Clinic and its patient data-sharing program to help track real-world performance of its current medical devices and help develop new ones.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has appointed Simon Campion as...